Associated Papers
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
Nannya Y et al.
Blood Advances, 2023
36989067 (PubMed )
Supplement: BLOODA_ADV-2022-009564-mmc2.xlsx › SuppTable2
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape
Zalmaï L et al.
Haematologica, 2021
33054115 (PubMed )
Supplement: 2020_253740_ZALMAI_SUPPL.pdf
Clonal hematopoiesis and risk of acute myeloid leukemia.
Young AL et al.
Haematologica, 2019
Genomic loss of HLA alleles may affect the clinical outcome in low-risk myelodysplastic syndrome patients.
Montes P et al.
Oncotarget, 2018
30651926 (PubMed )
Supplement: oncotarget-09-36929-s001.pdf
Integrative genetic analysis of mouse and human AML identifies cooperating disease alleles.
Hatlen MA et al.
The Journal of Experimental Medicine, 2016
26666262 (PubMed )
Supplement: supp_jem.20150524_JEM_20150524_sm.pdf
Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J et al.
Bmc Cancer, 2010
20678218 (PubMed )
Supplement: 1471-2407-10-401-S1.PDF
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.
Gelsi-Boyer V et al.
British Journal of Haematology, 2009
Select a paper to view details